Key facts
- This page summarizes Gilla Kaplan's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2026, 16:10.
Gilla Kaplan - 02 Jun 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)
- Reporting relationship
- Director
- Issuer ticker
- AVTX
- Reported as of
- 02 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2026, 16:10:13 UTC
- Prior SEC filing
- 31 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Sullivan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Gilla Kaplan filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 04 Jun 2026.
Change
- Previous filing in this sequence was filed on 31 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001247024
Primary reporting owner
KAPLAN GILLA
- Relationship
- Director
- Address
- C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
- Signature
- /s/ Christopher Sullivan, Attorney-in-Fact
- Signature date
- 04 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +20,100
- Change %
- Price
- $0.000000*
- Shares after
- 20,100
- Date
- 02 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,100
- Exercise price
- $13.96
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date.